Here is what the page “Novo CEO: Still Work to Do to Build Investor Confidence” contains. In an exclusive interview with Bloomberg Television, Novo CEO Mike Doustdar discusses the company's efforts to build investor confidence, its approach to drug testing, and the potential for expanding its obesity offerings. Doustdar acknowledges that there is still work to be done to reassure investors, emphasizing the importance of transparency and consistent performance.
"We should also have a mindset that we don't have a patent or a monopoly on all the good ideas," Doustdar tells Bloomberg. "When there is a gap, strategically or scientifically, we're looking outside to see how we can fill the gaps." This openness to external innovation reflects Novo's strategy to stay competitive in the rapidly evolving pharmaceutical landscape, particularly in the high-demand area of obesity treatments. For the complete material, the listing points back to the source inside the network.